This article is more than 5 years old. Information may no longer be current.
VIDEO: ANNEXA-R results exhibit ‘dramatic’ anticoagulation reversal with andexanet alfa
Click Here to Manage Email Alerts
ORLANDO, Fla. — Anthony N. DeMaria, MD, Jack and Judith White Chair in Cardiology at the University of California, San Diego, highlights potentially therapy-altering discoveries from the ANNEXA-R study presented at the annual AHA Scientific Sessions.
Specifically, DeMaria discusses data showing andexanet alfa (Portola Pharmaceuticals) is able to rapidly reverse the anticoagulant effects of rivaroxaban (Xarelto, Janssen Pharmaceuticals), in context of simultaneously published findings on apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) from the ANNEXA-A study.
“There has been some reluctance in the medical community to use these newer oral anticoagulants because of the lack of a reversal agent,” DeMaria said. “It would appear that we now have such an agent.”
He reviews the patient population and endpoints sought, details the “dramatic demonstration” of andexanet alfa countering the effects of Factor Xa inhibitors and touches on the investigation needed next.
“I predict that this will be an effective agent and will encourage more physicians to use the new oral anticoagulants,” DeMaria said.